Hence, Tandem Diabetes Care's Capex-to-Revenue for the
three
months ended in Sep. 2024 was 0.02.
Tandem Diabetes Care Capex-to-Revenue Historical Data
The historical data trend for Tandem Diabetes Care's Capex-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Tandem Diabetes Care's Capex-to-Revenue
For the Medical Devices subindustry, Tandem Diabetes Care's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tandem Diabetes Care's Capex-to-Revenue Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Tandem Diabetes Care's Capex-to-Revenue distribution charts can be found below:
* The bar in red indicates where Tandem Diabetes Care's Capex-to-Revenue falls into.
Tandem Diabetes Care Capex-to-Revenue Calculation
Tandem Diabetes Care's Capex-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tandem Diabetes Care (NAS:TNDM) Capex-to-Revenue Explanation
Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.
Tandem Diabetes Care Capex-to-Revenue Related Terms
Thank you for viewing the detailed overview of Tandem Diabetes Care's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Tandem Diabetes designs, manufactures, and markets durable insulin pumps for diabetes patients. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on a tubeless pump. Nearly three-quarters of total revenue is derived from the us, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one third is from disposable infusion sets that need to be changed over every 2 to 3 days.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
TNDM has been successfully added to your 